Lith-O-Asp
CAS: 881179-02-8
Category: Pharmaceutical Intermediates
| Purity | Research Grade ≥95%, High-Purity Grade ≥98%, Analytical Reference Standard ≥99% |
| Molecular Formula | C28H45NO6 |
| Molecular Weight | 491.7 |
| Appearance | White to off-white amorphous or crystalline powder |
| Packaging | 10mg/25mg/50mg/100mg/250mg/500mg/glass vial or plastic bottle (for research); 1g/5g/10g/aluminum foil bag or fiber drum; custom packaging for bulk orders |
| Testing Indicators | Appearance — Visual inspection; Identification — NMR (¹H, ¹³C, 2D-COSY, HSQC), FTIR (characteristic ester C=O ~1735 cm⁻¹, amide C=O ~1650–1680 cm⁻¹, carboxylic acid O-H broad ~2500–3500 cm⁻¹), or LC-MS/MS; Purity — HPLC (C18 column, UV detection at 210–220 nm or ELSD); Chiral purity — Chiral HPLC (if applicable); Melting point — Capillary method; Water content — Karl Fischer titration or loss on drying; Residual solvents — GC; Heavy metals — ICP-MS; Related impurities (unconjugated bile acid, free aspartic acid, hydrolysis products) — HPLC-MS; Mass verification — High-resolution mass spectrometry (HRMS); Optical rotation — Polarimetry. |
| Storage Notes | Stored in a tightly sealed container in a cool, dry, well-ventilated area, protected from light and moisture; away from strong oxidizers, strong acids, strong bases, and heat sources; store at -20°C for long-term stability (peptide bond may be labile); keep container closed when not in use. |
| Lead Time | days |
Used as a research chemical in bile acid metabolism and transporter studies; as a synthetic bile acid-amino acid conjugate for investigating enterohepatic circulation, farnesoid X receptor (FXR) activation, and Takeda G protein-coupled receptor 5 (TGR5) signaling; the aspartate (2-amino-3-carboxypropanoyl) moiety introduces additional negative charge and hydrogen bonding capacity; studied for potential therapeutic applications in cholestatic liver diseases, non-alcoholic steatohepatitis (NASH), and as drug delivery enhancers (permeation enhancers for oral peptide delivery); used in structure-activity relationship (SAR) studies of bile acid-based pharmaceuticals.